In Vitro Antifungal Susceptibility Testing of 5 Antifungal Agents against Dermatophytic Species by CLSI (M38-A) Micro Dilution Method

Introduction: Endometrial cancer is one of the most common malignancies of the female genital tract, which can be serious or life-threatening. Microbial infections can be one of the underlying causes of this type of cancer. Case Presentation: The present study describes the isolation of Pichia fermentans (Candida firmentaria var. firmentaria) from the vaginal secretions of a 61-year-old woman affected by endometrial cancer. She reported abdominal pain and vaginal discharge for 3 months, and had a history of diabetes, hypertension, Deep Vein Thrombosis (DVT), and Acute Myeloid Leukemia (AML). The isolated yeast was identified based on nuclear ribosomal internal transcribed spacer (ITS1-ITS2 rDNA) sequence analysis. The in vitro antifungal susceptibility testing showed a higher effect for ketoconazole against P. fermentans than fluconazole, itraconazole and voriconazole. Conclusion: Correct differentiation between P. fermentans and other yeast should be considered. The in vitro antifungal susceptibility testing is recommended for rare yeast, and will help the physicians in providing the best treatment.

Download Full-text

Isolation, Identification, and In Vitro Antifungal Susceptibility Testing of Dermatophytes from Clinical Samples at Sohag University Hospital in Egypt

Electronic physician ◽

10.19082/2557 ◽

2016 ◽

Vol 8 (6) ◽

pp. 2557-2567 ◽

Cited By ~ 8

Author(s):

Mona Fattouh Mohamed Shalaby ◽

Asmaa Nasr El-din ◽

Mohammed Abu El-Hamd

Keyword(s):

Susceptibility Testing ◽

Antifungal Susceptibility ◽

Antifungal Susceptibility Testing ◽

University Hospital ◽

Clinical Samples ◽

In Vitro Antifungal Susceptibility

Download Full-text

Comparison of Disk Diffusion and Broth Microdilution Methods for in Vitro Antifungal Susceptibility Testing of Dermatophytes

Indian Journal of Medical Microbiology ◽

10.1016/j.ijmmb.2021.08.339 ◽

2021 ◽

Vol 39 ◽

pp. S97-S98

Author(s):

Safiya Firoze

Keyword(s):

Susceptibility Testing ◽

Antifungal Susceptibility ◽

Antifungal Susceptibility Testing ◽

Disk Diffusion ◽

Broth Microdilution ◽

In Vitro Antifungal Susceptibility

Download Full-text

Standardized Method for In Vitro Antifungal Susceptibility Testing of Candida albicansBiofilms

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.45.9.2475-2479.2001 ◽

2001 ◽

Vol 45 (9) ◽

pp. 2475-2479 ◽

Cited By ~ 464

Author(s):

Gordon Ramage ◽

Kacy Vande Walle ◽

Brian L. Wickes ◽

José L. López-Ribot

Keyword(s):

Antimicrobial Agents ◽

Susceptibility Testing ◽

Colorimetric Assay ◽

Antifungal Susceptibility ◽

Antifungal Susceptibility Testing ◽

Phenotypic Traits ◽

Salt Reduction ◽

Treatment Regimens ◽

In Vitro Antifungal Susceptibility

ABSTRACT Candida albicans is implicated in many biomaterial-related infections. Typically, these infections are associated with biofilm formation. Cells in biofilms display phenotypic traits that are dramatically different from those of their free-floating planktonic counterparts and are notoriously resistant to antimicrobial agents. Consequently, biofilm-related infections are inherently difficult to treat and to fully eradicate with normal treatment regimens. Here, we report a rapid and highly reproducible microtiter-based colorimetric assay for the susceptibility testing of fungal biofilms, based on the measurement of metabolic activities of the sessile cells by using a formazan salt reduction assay. The assay was used for in vitro antifungal susceptibility testing of severalC. albicans strains grown as biofilms against amphotericin B and fluconazole and the increased resistance of C. albicans biofilms against these antifungal agents was demonstrated. Because of its simplicity, compatibility with a widely available 96-well microplate platform, high throughput, and automation potential, we believe this assay represents a promising tool for the standardization of in vitro antifungal susceptibility testing of fungal biofilms.

Download Full-text

ANTIFUNGAL SUSCEPTIBILITY TESTING: CURRENT ROLE FROM THE CLINICAL LABORATORY PERSPECTIVE

Mediterranean Journal of Hematology and Infectious Diseases ◽

10.4084/mjhid.2014.030 ◽

2014 ◽

Vol 6 (1) ◽

pp. e2014030 ◽

Cited By ~ 12

Author(s):

Brunella Posteraro ◽

Riccardo Torelli ◽

Elena De Carolis ◽

Patrizia Posteraro ◽

Maurizio Sanguinetti

Keyword(s):

Drug Exposure ◽

Antifungal Agents ◽

Susceptibility Testing ◽

Clinical Laboratory ◽

Antifungal Susceptibility ◽

Antifungal Susceptibility Testing ◽

Clinical Resistance ◽

Therapeutic Decision Making ◽

Short Time

Despite availability of many antifungal agents, antifungal clinical resistance occurs, perhaps as a result of an infecting organism found to be resistant in vitro to one or more antifungals tested. Thus, antifungal susceptibility testing (AFST) results, if timely generated by the clinical microbiology and communicated to clinicians, can aid them in the therapeutic decision making, especially for difficult-to-treat invasive candidiasis and aspergillosis. Although recently refined AFST methods are commercially available to allow a close antifungal resistance surveillance in many clinical setting, novel assays, relying on short-time antifungal drug exposure of fungal isolates, are upcoming tools for AFST. Based on emerging technologies such as flow cytometry, MALDI-TOF mass spectrometry, and isothermal microcalorimetry, these assays could provide a reliable means for quicker and sensitive assessment of AFST.

Download Full-text